Roche Group has completed the acquisition of Carmot Therapeutics, a clinical-stage biotechnology company committed to advancing transformative therapeutics for individuals grappling with metabolic disorders, such as obesity and diabetes.
Through the acquisition, Roche gains access to Carmot’s comprehensive Research and Development (R&D) portfolio, encompassing both clinical and pre-clinical assets.
Additionally, Roche secures exclusive rights to Carmot’s groundbreaking Chemotype Evolution discovery platform in metabolism, significantly enhancing Roche’s R&D initiatives and bolstering its portfolio in cardiovascular and metabolic diseases.
Carmot, along with its personnel, will now be integrated into the Roche Group as part of the Pharmaceuticals Division.
The strategic move enables Roche to tap into Carmot’s distinctive array of incretins, which includes:
CT-388: The primary asset, positioned for Phase-2 readiness, is a dual GLP-1/GIP receptor agonist designed to address obesity in patients with and without type 2 diabetes. Administered subcutaneously once a week, it holds promise as a standalone therapy and as part of combination treatments, aiming to enhance weight loss and potentially extend its applications to other medical indications.
CT-996: A once-daily oral, small molecule GLP-1 receptor agonist currently in Phase-1, intended for treating obesity in patients with and without type 2 diabetes.
CT-868: Positioned in Phase-2, this once-daily subcutaneous injectable is a dual GLP-1/GIP receptor agonist intended for addressing overweight or obesity in patients with type 1 diabetes.
Roche has acquired all outstanding shares and options of Carmot, completing the transaction at a purchase price of $2.7bn. Moreover, Carmot’s equity holders stand to receive additional payments, totalling up to $400m, contingent on the accomplishment of specific milestones.
